George L. Sing

George L. Sing (board member) discloses dealings in Regeneron Pharmaceuticals, Inc. to SEC (Form 4). Between 9 January 2006 and 2 November 2026, the trades on record add up to 205 filings.

Both buying and selling appear: 5 purchases worth €330k, against 144 sales worth €143.1M. On balance, insiders were net sellers of €142.8M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 11 share grants and 42 option exercises. So far in 2026, the count stands at no purchases and 9 sales.

The median purchase comes to €58k. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 60% of cases; the median change was +48.3%. These figures describe past trades and do not predict future prices.

On 4 November 2026 came the latest disclosure, an option exercise for €2.6M in Regeneron Pharmaceuticals, Inc. The clock since the last published purchase (19 May 2010) now reads 6,017 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.